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reductase activity for TECR (GPSN2), 
confirming an earlier study, which had 
identified fatty acids as the substrates of 
this steroid 5α-reductase family member 
(Figure 1B) (Moon and Horton, 2003).
The work of Cantagrel and coworkers 
is creatively exhaustive and nails down 
every aspect of a difficult research prob-
lem from yeast cultures to the clinic. 
Where could they possibly go from here? 
For one, their studies in mice with muta-
tions in Srd5a3 suggest a regulatory 
crosstalk between the mevalonate path-
way and N-linked protein glycosylation, 
and it will be interesting to determine the 
mechanism underlying this interplay. In 
addition, the substrate and physiological 
function of SRD5A2L are still unknown. 
Will this steroid 5α-reductase function in 
glycosylation or hormone production, or 
will it play a completely distinct role from 
that of its namesake?
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279–306.Bone remodeling is a highly conserved 
and regulated process that controls 
calcium homeostasis within a very tight 
range and maintains the structural integ-
rity of the skeleton. In this issue of Cell, 
tandem articles from independent labo-
ratories (Fulzele et al., 2010; Ferron et 
al., 2010) provide fresh support for the 
hypothesis that the insulin regulatory sys-
tem mediates communication between 
metabolic control and bone remodeling. 
Fulzele et al. (2010) provide compelling in 
vivo evidence, using conditional deletion 
of the insulin receptor in osteoblasts, 
that insulin signaling promotes bone 
formation by suppressing an inhibi-
tor of osteoblast development, Twist2, 
and enhances expression of osteocal-
cin, a mediator of insulin sensitivity and 
secretion. Ferron et al. (2010) show that 
insulin signaling in osteoblasts mediates 
glucose homeostasis by stimulating the 
production of an inactive form of osteo-
calcin and by promoting osteoclast-
mediated bone resorption, which then 
releases the active form of osteocalcin. 
In this putative feed-forward loop, the 
complete bone remodeling process is 
involved, thereby linking skeletal homeo-
stasis to energy regulation. Given that 
the findings from these papers may have 
profound implications for understanding 
and ultimately treating several metabolic 
conditions, a closer examination of these 
two reports is necessary to clarify where 
and how this regulatory loop is situated 
in the hierarchy of control mechanisms 
that define insulin signaling and bone 
turnover.
It has only been a decade since Ducy 
et al. (2000) demonstrated that leptin (an 
adipokine that regulates appetite, energy 
expenditure, and insulin secretion) influ-
ences bone remodeling through hypo-
thalamic modulation of the sympathetic 
nervous system. Prior to that, skeletal 
remodeling was considered within its 
essential context of calcium conserva-
tion, a homeostatic process regulated 
by calciotropic hormones (such as 
parathyroid hormone and vitamin D), 
gonadal steroids (such as estrogen), and 
local growth factors (such as insulin-like 
growth factor I and transforming growth 
factor β). Subsequent work has provided 
stronger support for the tenet that lep-
tin is a major, albeit indirect, mediator 
of skeletal turnover through neuronal 
circuits in the central nervous system 
(Lee et al., 2007; Yoshizawa et al., 2009). 
In addition the osteoblast-specific pro-
tein osteocalcin is reported to promote 
insulin secretion (Hinoi et al., 2008; Fer-
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Advancing the hypothesis that bone remodeling is intimately linked to metabolic homeostasis, 
Fulzele et al. (2010) and Ferron et al. (2010) present evidence that insulin signaling promotes 
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ron et al., 2008). Interest-
ingly, osteocalcin undergoes 
gamma carboxylation in a 
vitamin K-dependent process 
prior to its secretion, although 
a relatively small fraction of 
osteocalcin is undercarboxy-
lated and is released into 
the circulation. It is the lat-
ter form that is postulated to 
be active on adipocytes and 
insulin-producing pancreatic 
beta cells (Figure 1) (Lee et 
al., 2007).
Several lines of evidence 
from the two new papers 
strengthen the proposal that 
osteocalcin is indeed the 
skeletal mediator of energy 
balance. For example, mice 
lacking osteocalcin have a 
metabolic phenotype nearly 
identical to that of mice with 
conditional deletion of the 
insulin receptor in osteo-
blasts. In addition, Fuzele et 
al. improve insulin sensitivity 
in mice lacking expression of 
the insulin receptor in osteo-
blasts with a 2 week infusion 
of undercarboxylated osteo-
calcin. Despite this treatment, 
the mice remain glucose intol-
erant, most likely as a result 
of a decrease in beta cell mass from 
chronic insulin resistance. Determin-
ing whether chronic infusions of under-
carboxylated osteocalcin could fully 
rescue both the metabolic and obesity 
phenotypes of these mice will be critical 
for placing this protein in the regulatory 
hierarchy that controls insulin secretion 
and will provide an indicator of its future 
therapeutic utility.
The work by Ferron et al. rein-
forces the findings of Fuzele et al. and 
addresses some, but not all, of the 
questions raised since the Karsenty 
group first introduced the concept that 
the skeleton could regulate energy 
metabolism (Lee et al., 2007; Hinoi et 
al., 2008). In prior work, osteocalcin has 
been shown to be regulated by the Esp 
gene, which encodes osteotesticular 
protein tyrosine phosphatase (OST-
PTP). However, it has been unknown 
how OST-PTP suppresses levels of 
undercarboxylated osteocalcin. Using 
substrate trapping, Ferron et al. now 
identify a direct interaction between the 
insulin receptor and OST-PTP resulting 
in dephosphorylation and subsequent 
inactivation of the insulin receptor. In 
mice lacking OST-PTP, insulin sensitiv-
ity and secretion is markedly enhanced 
as a result of constitutive activation of 
the receptor. Osteoblast-specific dele-
tion of one allele of the insulin recep-
tor ameliorates the high levels of active 
undercarboxylated osteocalcin and 
normalizes the insulin tolerance of OST-
PTP deficient mice.
A second issue has been the absence 
of a clearly defined link between bone 
turnover by insulin receptor activation 
and undercarboxylated osteocalcin. 
Intriguingly, in the conditional insu-
lin receptor null mice, bone resorp-
tion is markedly reduced, whereas 
bone resorption is high in mice lacking 
OST-PTP. A prior report by Ferron and 
colleagues (Ferron et al., 2008) indi-
cates that these changes 
are due to altered expres-
sion of osteoblast-derived 
osteoprotegerin (OPG), a 
secreted inhibitor of osteo-
clast maturation and activity. 
Although osteoclasts do not 
make osteocalcin, it has long 
been recognized that matrix-
derived osteocalcin can enter 
the circulation in substantial 
amounts during bone resorp-
tion. The new data from Fer-
ron et al. clearly show that 
the acidic environment of the 
resorption pit is sufficient to 
decarboxylate, and there-
fore activate, osteocalcin. In 
support of this notion, when 
RANKL (receptor activator 
for nuclear factor κB ligand), 
the most powerful endog-
enous stimulators of resorp-
tion by osteoclasts, is admin-
istered to wild-type mice, 
undercarboxylated osteocalcin 
increases 3-fold. In contrast, 
mice with nonfunctional osteo-
clasts have reduced levels of 
undercarboxylated osteocalcin 
and exhibit a nearly identical 
metabolic phenotype to mice 
lacking osteocalcin. Moreover, 
reduction of osteoclast resorp-
tion with bisphosphonates rescues the 
enhanced insulin secretion and glucose 
tolerance observed in OST-PTP-deficient 
mice.
A third concern raised from earlier 
data relates to the absence of a human 
homolog for the Esp gene. Ferron again 
use substrate trapping with PTP1B, a 
tyrosine phosphatase in humans that 
dephosphorylates the insulin receptor, 
and show that decreasing expression 
of PTP1B with a small interfering RNA 
suppresses osteoprotegerin expres-
sion in vitro. Finally the authors present 
data from osteopetrotic patients (that is, 
individuals with impaired bone resorp-
tion) showing reduced serum undercar-
boxylated osteocalcin levels compared 
to controls, as well as impaired insulin 
secretion after a meal.
Despite these remarkable data, ques-
tions remain. First and foremost, there 
is still no known osteocalcin receptor. 
Hence, the mechanism of how under-
figure 1. energy Regulation and Bone Turnover by the Insulin/ 
Osteocalcin Axis
A putative feed-forward regulatory loop ties bone turnover to energy regulation 
as proposed by Ferron et al. (2010) and Fulzele et al. (2010). Insulin activates 
skeletal remodeling (that is, increases bone formation by osteoblasts and re-
sorption by osteoclasts), which in turn releases uncarboxylated osteocalcin 
from the skeletal matrix into the circulation. This enhances insulin secretion 
and increases the insulin sensitivity of adipocytes. A tyrosine phosphatase 
OST-PTP, which is encoded by the Esp gene, binds the insulin receptor (IR) 
and suppresses its activation through dephosphorylation. The transcription 
factor Twist2 is a critical downstream suppressor of osteoblast differentiation. 
Osteoprotegerin (OPG) is an osteoblast-specific inhibitor of RANKL, acting 
as a decoy receptor to block bone resorption. Hydroxyapatite is the mineral 
component of bone.Cell 142, July 23, 2010 ©2010 Elsevier Inc. 199
carboxylated osteocalcin increases 
pancreatic insulin production and 
secretion is not clear. Second, if bone 
resorption is so critical to the posttrans-
lational modification of osteocalcin and 
therefore insulin secretion, are individu-
als on antiresorptive therapy for osteo-
porosis more likely to be insulin resis-
tant and glucose intolerant? In a small 
observational study, Kaji et al. (2009) 
report that fasting glucose levels are 
higher in women treated for 2 years with 
alendronate, the most commonly used 
treatment for osteoporosis. However, fat 
mass does not differ in these patients, 
and the statistical relationship between 
bone density and fasting glucose dis-
appears when corrected for changes in 
lean mass. In addition, previous human 
investigations clearly demonstrate that 
an oral glucose load that increases 
insulin secretion suppresses markers of 
bone resorption by 50% (Clowes et al., 
2003). Most importantly, and yet much 
more difficult to address, is whether the 
relationship between bone and energy 
metabolism provides an evolutionary 
advantage and, if so, where skeletal 
control fits into the complex hierarchy 
of acute and chronic regulation of insu-
lin secretion during physiologic states. 
Notwithstanding these unanswered 
questions, these two studies provide a 
strong framework for understanding the 
emerging role of the skeleton in meta-
bolic homeostasis.
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Life is all about capturing energy and 
putting it to use seeking more energy, 
avoiding being someone else’s energy, 
building and repairing parts, and mak-
ing more life. In eukaryotic cells, the 
mitochondria are the processing plants 
where the major forms of energy cur-
rency, such as ATP, are generated by 
catabolism of nutrients and consump-
tion of oxygen. Much of mitochon-
drial research of the last 50 years has 
focused on how this flow and con-
version of energy is controlled. But 
it is only in the last few years that we 
have realized that this process is an 
important node in the complex signal 
transduction machinery that extends 
throughout the cell and connects it to 
the external environment. In a sense, 
we are seeking the links between infor-
mation and energy in the cell. Now, a 
paper in this issue provides one such 
link: Cardenas et al. (2010) report that 
calcium constitutively released from 
the endoplasmic reticulum (ER) by 
the inositol 1,4,5-triphosphate recep-
tor (IP3R) is taken up by mitochondria 
where it is required for efficient oxygen 
consumption and ATP production.
When eukaryotic cells are starved of 
nutrients, they engage the process of 
autophagy to catabolize themselves to 
survive, and this is generally triggered by 
calcium and energy:  
Making the cake and eating It too?
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Mitochondrial calcium ions promote a number of events that sustain ATP levels in the cell. Cardenas 
et al. (2010) now demonstrate that the inositol 1,4,5-triphosphate receptor at the endoplasmic 
reticulum constitutively provides calcium for mitochondria. In the absence of this calcium transfer, 
cells use autophagy to sustain survival.
